B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
The Lymphoma Academic Research Organisation
University of Arizona
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
The First Affiliated Hospital with Nanjing Medical University
Incyte Corporation
Janssen Research & Development, LLC